Biotechnology Value Trading Fund OS LP
CIK 0001660683 Name as filed on the most recent filing
Filed as Biotechnology Value Trading Fund OS LP (141)
555 transaction lines · from 141 filings · filed 2016-01-11 to 2026-06-26 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
- ISSUER Kymera Therapeutics, Inc. 11 filings
- ISSUER MoonLake Immunotherapeutics 2 filings
- ISSUER Essa Pharma Inc. 1 filings
- ISSUER Xoma Royalty Corp 25 filings
- ISSUER Third Harmonic Bio, Inc. 2 filings
- ISSUER Eledon Pharmaceuticals, Inc. 2 filings
- ISSUER Point Biopharma Global Inc. 1 filings
- ISSUER Repare Therapeutics Inc. 6 filings
- ISSUER Olema Pharmaceuticals, Inc. 4 filings
- ISSUER Rain Therapeutics Inc. 9 filings
- ISSUER CTI Biopharma Corp 4 filings
- ISSUER Cullinan Oncology, Inc. 3 filings
- ISSUER Merus N.V. 14 filings
- ISSUER Infinity Pharmaceuticals, Inc. 13 filings
- ISSUER Ideaya Biosciences, Inc. 3 filings
- ISSUER Cytokinetics Inc 3 filings
- ISSUER Five Prime Therapeutics, Inc. 12 filings
- ISSUER Glycomimetics Inc 3 filings
- ISSUER Calithera Biosciences, Inc. 4 filings
- ISSUER Pieris Pharmaceuticals, Inc. 1 filings
- ISSUER Concert Pharmaceuticals, Inc. 3 filings
- ISSUER Immune Design Corp. 1 filings
- ISSUER Arqule Inc 3 filings
- ISSUER Xenon Pharmaceuticals Inc. 6 filings
- ISSUER Nivalis Therapeutics, Inc. 5 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-26 |
Kymera Therapeutics, Inc. KYMR |
S, Open-market sale | 837,914 disposed | 106.50 | 89,237,841.00 | Form 4, filing 0000921895-26-001688 | |
| 2026-06-26 |
Kymera Therapeutics, Inc. KYMR |
S, Open-market sale | 627,597 disposed | 106.50 | 66,839,080.50 | Form 4, filing 0000921895-26-001688 | |
| 2026-06-26 |
Kymera Therapeutics, Inc. KYMR |
S, Open-market sale | 113,289 disposed | 106.50 | 12,065,278.50 | Form 4, filing 0000921895-26-001688 | |
| 2026-06-26 |
Kymera Therapeutics, Inc. KYMR |
S, Open-market sale | 51,858 disposed | 106.50 | 5,522,877.00 | Form 4, filing 0000921895-26-001688 | |
| 2026-03-31 |
MoonLake Immunotherapeutics MLTX |
S, Open-market sale | 1,932,354 disposed | 16.79 | 32,444,223.66 | Form 4, filing 0000921895-26-000895 | |
| 2026-03-31 |
MoonLake Immunotherapeutics MLTX |
S, Open-market sale | 1,569,116 disposed | 16.79 | 26,345,457.64 | Form 4, filing 0000921895-26-000895 | |
| 2026-03-31 |
MoonLake Immunotherapeutics MLTX |
S, Open-market sale | 248,530 disposed | 16.79 | 4,172,818.70 | Form 4, filing 0000921895-26-000895 | |
| 2025-08-05 |
Essa Pharma Inc. EPIX |
S, Open-market sale | 79 disposed | 1.88 | 148.35 | Form 4, filing 0000921895-25-002133 | |
| 2025-08-05 |
Essa Pharma Inc. EPIX |
S, Open-market sale | 66 disposed | 1.88 | 123.94 | Form 4, filing 0000921895-25-002133 | |
| 2025-08-05 |
Essa Pharma Inc. EPIX |
S, Open-market sale | 11 disposed | 1.88 | 20.66 | Form 4, filing 0000921895-25-002133 | |
| 2025-06-30 |
Kymera Therapeutics, Inc. KYMR |
P, Open-market purchase | 142,604 acquired | 44.00 | 6,274,576.00 | Form 4, filing 0000921895-25-001910 | |
| 2025-06-30 |
Kymera Therapeutics, Inc. KYMR |
P, Open-market purchase | 115,783 acquired | 44.00 | 5,094,452.00 | Form 4, filing 0000921895-25-001910 | |
| 2025-06-30 |
Kymera Therapeutics, Inc. KYMR |
P, Open-market purchase | 58,780 acquired | 44.00 | 2,586,320.00 | Form 4, filing 0000921895-25-001910 | |
| 2025-05-16 |
Xoma Royalty Corp XOMA |
S, Open-market sale | 265,316 disposed | 27.10 | 7,190,063.60 | Form 4, filing 0000921895-25-001602 | |
| 2025-05-16 |
Xoma Royalty Corp XOMA |
S, Open-market sale | 127,407 disposed | 27.10 | 3,452,729.70 | Form 4, filing 0000921895-25-001602 | |
| 2025-01-24 |
Xoma Royalty Corp XOMA |
S, Open-market sale | 339,679 disposed | 26.10 | 8,865,621.90 | Form 4, filing 0000921895-25-000177 | |
| 2025-01-24 |
Xoma Royalty Corp XOMA |
S, Open-market sale | 149,975 disposed | 26.10 | 3,914,347.50 | Form 4, filing 0000921895-25-000177 | |
| 2025-01-24 |
Xoma Royalty Corp XOMA |
S, Open-market sale | 85,776 disposed | 26.10 | 2,238,753.60 | Form 4, filing 0000921895-25-000177 | |
| 2025-01-24 |
Xoma Royalty Corp XOMA |
S, Open-market sale | 75,287 disposed | 26.10 | 1,964,990.70 | Form 4, filing 0000921895-25-000177 | |
| 2024-10-29 |
Third Harmonic Bio, Inc. THRD |
S, Open-market sale | 538,420 disposed | 14.30 | 7,699,406.00 | Form 4, filing 0000921895-24-002409 | |
| 2024-10-29 |
Third Harmonic Bio, Inc. THRD |
S, Open-market sale | 396,963 disposed | 14.30 | 5,676,570.90 | Form 4, filing 0000921895-24-002409 | |
| 2024-10-29 |
Third Harmonic Bio, Inc. THRD |
S, Open-market sale | 64,617 disposed | 14.30 | 924,023.10 | Form 4, filing 0000921895-24-002409 | |
| 2024-10-04 |
MoonLake Immunotherapeutics MLTX |
S, Open-market sale | 1,030,589 disposed | 50.00 | 51,531,098.94 | Form 4, filing 0000921895-24-002263 | |
| 2024-10-04 |
MoonLake Immunotherapeutics MLTX |
S, Open-market sale | 836,862 disposed | 50.00 | 41,844,438.98 | Form 4, filing 0000921895-24-002263 | |
| 2024-10-04 |
MoonLake Immunotherapeutics MLTX |
S, Open-market sale | 132,549 disposed | 50.00 | 6,627,662.08 | Form 4, filing 0000921895-24-002263 | |
| 2024-05-09 |
Eledon Pharmaceuticals, Inc. ELDN |
P, Open-market purchase | 1,031,385 acquired | Not reported | Not priced | Form 4, filing 0000921895-24-001131 | |
| 2024-05-09 |
Eledon Pharmaceuticals, Inc. ELDN |
P, Open-market purchase | 821,121 acquired | Not reported | Not priced | Form 4, filing 0000921895-24-001131 | |
| 2024-05-09 |
Eledon Pharmaceuticals, Inc. ELDN |
P, Open-market purchase | 75,431 acquired | Not reported | Not priced | Form 4, filing 0000921895-24-001131 | |
| 2023-12-18 |
Point Biopharma Global Inc. PNT |
S, Open-market sale | 8,974,245 disposed | 12.45 | 111,729,350.25 | Form 4, filing 0001193805-23-001635 | |
| 2023-12-18 |
Point Biopharma Global Inc. PNT |
S, Open-market sale | 7,290,667 disposed | 12.45 | 90,768,804.15 | Form 4, filing 0001193805-23-001635 | |
| 2023-12-18 |
Point Biopharma Global Inc. PNT |
S, Open-market sale | 896,366 disposed | 12.45 | 11,159,756.70 | Form 4, filing 0001193805-23-001635 | |
| 2023-11-16 |
Repare Therapeutics Inc. RPTX |
P, Open-market purchase | 153,693 acquired | 5.38 | 827,437.00 | Form 4, filing 0000921895-23-002669 | |
| 2023-11-16 |
Repare Therapeutics Inc. RPTX |
P, Open-market purchase | 125,909 acquired | 5.38 | 677,856.28 | Form 4, filing 0000921895-23-002669 | |
| 2023-11-16 |
Repare Therapeutics Inc. RPTX |
P, Open-market purchase | 16,143 acquired | 5.38 | 86,909.07 | Form 4, filing 0000921895-23-002669 | |
| 2023-11-15 |
Repare Therapeutics Inc. RPTX |
P, Open-market purchase | 493,337 acquired | 5.00 | 2,466,635.67 | Form 4, filing 0000921895-23-002669 | |
| 2023-11-15 |
Repare Therapeutics Inc. RPTX |
P, Open-market purchase | 390,507 acquired | 5.00 | 1,952,495.95 | Form 4, filing 0000921895-23-002669 | |
| 2023-11-15 |
Repare Therapeutics Inc. RPTX |
P, Open-market purchase | 47,712 acquired | 5.00 | 238,555.23 | Form 4, filing 0000921895-23-002669 | |
| 2023-11-03 |
Kymera Therapeutics, Inc. KYMR |
P, Open-market purchase | 103,885 acquired | 14.07 | 1,461,547.68 | Form 4, filing 0000921895-23-002475 | |
| 2023-11-03 |
Kymera Therapeutics, Inc. KYMR |
P, Open-market purchase | 83,708 acquired | 14.07 | 1,177,679.48 | Form 4, filing 0000921895-23-002475 | |
| 2023-11-03 |
Kymera Therapeutics, Inc. KYMR |
P, Open-market purchase | 10,106 acquired | 14.07 | 142,180.30 | Form 4, filing 0000921895-23-002475 | |
| 2023-11-02 |
Kymera Therapeutics, Inc. KYMR |
P, Open-market purchase | 132,016 acquired | 11.64 | 1,537,247.11 | Form 4, filing 0000921895-23-002475 | |
| 2023-11-02 |
Kymera Therapeutics, Inc. KYMR |
P, Open-market purchase | 57,618 acquired | 11.64 | 670,927.04 | Form 4, filing 0000921895-23-002475 | |
| 2023-11-02 |
Kymera Therapeutics, Inc. KYMR |
P, Open-market purchase | 26,772 acquired | 11.64 | 311,743.88 | Form 4, filing 0000921895-23-002475 | |
| 2023-11-02 |
Repare Therapeutics Inc. RPTX |
P, Open-market purchase | 492,251 acquired | 3.60 | 1,772,103.60 | Form 4, filing 0000921895-23-002458 | |
| 2023-11-02 |
Repare Therapeutics Inc. RPTX |
P, Open-market purchase | 218,979 acquired | 3.60 | 788,324.40 | Form 4, filing 0000921895-23-002458 | |
| 2023-11-02 |
Repare Therapeutics Inc. RPTX |
P, Open-market purchase | 72,479 acquired | 3.60 | 260,924.40 | Form 4, filing 0000921895-23-002458 | |
| 2023-09-12 |
Olema Pharmaceuticals, Inc. OLMA |
P, Open-market purchase | 775,278 acquired | 9.84 | 7,628,735.52 | Form 4, filing 0000921895-23-002167 | |
| 2023-09-12 |
Olema Pharmaceuticals, Inc. OLMA |
P, Open-market purchase | 677,853 acquired | 9.84 | 6,670,073.52 | Form 4, filing 0000921895-23-002167 | |
| 2023-09-12 |
Olema Pharmaceuticals, Inc. OLMA |
P, Open-market purchase | 52,801 acquired | 9.84 | 519,561.84 | Form 4, filing 0000921895-23-002167 | |
| 2023-05-05 |
Eledon Pharmaceuticals, Inc. ELDN |
P, Open-market purchase | 1,055,445 acquired | Not reported | Not priced | Form 4, filing 0000921895-23-001098 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Biotechnology Value Trading Fund OS LP, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001660683
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6